Intrastromal injection of bevacizumab in patients with corneal neovascularization
نویسندگان
چکیده
منابع مشابه
Intrastromal injection of bevacizumab in patients with corneal neovascularization.
Corneal neovascularization (NV) not only reduces visual acuity, but it also causes loss of the cornea's immune privilege, strongly contributing to a worse prognosis in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, and the role of vascular endothelial growth factor (VEGF) has been extensively proven. Anti-VEGF agents have been shown to be effective in slowing t...
متن کاملIntrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes
Introduction. Corneal neovessels are a major risk factor for corneal graft rejection, due to the loss of the immune privilege. The purpose of this study is to evaluate the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovascularization. Material and Methods. This is a prospective study that included 25 eyes of 22 patients with deep corneal neovessels, treat...
متن کاملSubconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
PURPOSE We report on the use of subconjunctival bevacizumab on corneal vessel density in recurrent pterygia. METHODS The charts of 5 patients with recurrent pterygium, who received subconjunctival injections of bevacizumab (2.5 mg/0.1 ml) were retrospectively reviewed. Ophthalmic evaluation included Snellen visual acuity (VA), tonometry and complete examination before the injection and at 1 w...
متن کاملIntravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization
We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...
متن کاملRanibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractory corneal NV despite two previous subconjunctival and intrastromal bevacizu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arquivos Brasileiros de Oftalmologia
سال: 2012
ISSN: 0004-2749
DOI: 10.1590/s0004-27492012000400012